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Abstract: Quantitative structure–activity relationship (QSAR) studies were performed in 
order to identify molecular features responsible for the antileishmanial activity of 61 
adenosine analogues acting as inhibitors of the enzyme glyceraldehyde 3-phosphate 
dehydrogenase of Leishmania mexicana (LmGAPDH). Density functional theory (DFT) 
was employed to calculate quantum-chemical descriptors, while several structural 
descriptors were generated with Dragon 5.4. Variable selection was undertaken with the 
ordered predictor selection (OPS) algorithm, which provided a set with the most relevant 
descriptors to perform PLS, PCR and MLR regressions. Reliable and predictive models 
were obtained, as attested by their high correlation coefficients, as well as the agreement 
between predicted and experimental values for an external test set. Additional validation 
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procedures were carried out, demonstrating that robust models were developed, providing 
helpful tools for the optimization of the antileishmanial activity of adenosine compounds. 
Keywords: adenosine compounds; antileishmanial activity; glyceraldehyde 3-phosphate 
dehydrogenase; DFT; multivariate regression 
 
1. Introduction 
Leishmaniases are diseases caused by the intracellular protozoan parasite Leishmania. There are an 
estimated 1.5–2 million new cases per year, of which up to 500,000 are visceral leishmaniasis (VL), 
the fatal version of the disease. Left untreated, it causes a global annual mortality estimated at 59,000 [1]. 
According to disease burden estimates, leishmaniasis ranks third in disease burden in disability-adjusted 
life years caused by neglected tropical diseases and is the second cause of parasite-related deaths after 
malaria [2]. For a variety of reasons, it is not receiving the deserved attention given its high occurrence [3]. 
The first-line treatments for VL since the 1930s are the pentavalent antimonials, although these 
compounds are toxic and resistance has been an increasing problem in India [4]. While significant 
progress has been made in the last 10 years, with the approval of amphotericin B, miltefosine and 
paromomycin, these new and safer chemotherapy alternatives remain out of reach for the affected rural 
population who are most in need [5]. Moreover, the use of poor-quality drugs can be life-threatening 
for vulnerable patients and also have a devastating impact on public health and elimination 
programmes targeting the disease [6]. 
The glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH) has been considered 
as a target for the inhibition of protozoan parasites [7,8]. GAPDH from the pathogenic 
trypanosomatids Trypanosoma brucei, Trypanosoma cruzi and Leishmania mexicana are quite similar 
to each other, but have sufficient structural differences, when compared to the human enzyme, making 
possible the structure-based design of compounds that selectively inhibit all three trypanosomatid 
enzymes, but not the human homologue [7]. 
By exploiting the differences in the structure of the parasitic and human GAPDH, adenosine 
analogs with substitutions on N-6 of the adenine ring and on the 2′ position of the ribose moiety were 
designed, synthesized and tested for inhibition of trypanosomatid GAPDHs, and two crystal structures 
of L. mexicana GAPDH (LmGAPDH) complexed with high-affinity inhibitors that also block parasite 
growth were solved [9]. Induced fit of the LmGAPDH backbone upon binding of the inhibitor may 
enlarge a cavity at the binding site to accommodate the inhibitor. The extensive hydrophobic 
interactions between the protein and the two substituents on the adenine scaffold of the inhibitor  
TND (N-1,2,3,4-tetrahydronaphth-1-yl-2′-[3,5-dimethoxybenzamido]-2′-deoxyadenosine), as shown in 
Figure 1, provide a plausible explanation for the high affinity of these inhibitors for trypanosomatid 
GAPDHs [9]. 
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Figure 1. Interactions between key aminoacid residues of LmGAPDH and inhibitor TND 
(image generated with PoseView [10], from crystallographic coordinates extracted from 
Protein Data Bank, code: 1I33). 
 
In order to enhance the knowledge on structural requirements for the adenosine binding to 
LmGAPDH, structure-activity relationship studies were carried out employing different molecular 
modeling techniques [11,12]. In this work we have performed the calculation of a large amount of 
electronic, geometrical and topological descriptors with the aim to select the most relevant ones to the 
biological activity of adenosine compounds as inhibitors of LmGAPDH, employing the recently 
developed variable selection algorithm OPS (Ordered Predictor Selection) [13]. By employing this 
strategy in conjunction with a protocol described previously [14,15], we have been able to construct a 
predictive model of the quantitative structure-activity relationships for the inhibition of LmGAPDH by 
adenosine compounds. 
2. Results and Discussion 
2.1. Statistical Results 
The OPS variable selection algorithm selected nine descriptors as the most relevant for the analysis: 
volume, EHOMO, HATS4e, HATS3u, H7m, Mor23v, BELp1, JGI2, E1v (see Table 1 for the meanings 
of each descriptor). 
Table 1. Symbols, types and definitions of the selected descriptors. 
Descriptor Type Definition 
Volume Geometric Solvent-accessible surface-bounded molecular volume 
EHOMO Electronic Energy of the highest occupied molecular orbital 
HATS4e GETAWAY Leverage-weighted autocorrelation of lag 4/weighted by atomic Sanderson 
electronegativities 
HATS3u GETAWAY Leverage-weighted autocorrelation of lag 3/unweighted 
H7m GETAWAY H autocorrelation of lag 2/weighted by atomic masses 
Mor23v 3D-MoRSE 3D-MoRSE-signal 23/weighted by atomic van der Waals volumes 
BELp1 BCUT Lowest eigenvalue n.1 of Burden matrix/weighted by atomic polarizabilities 
JGI2 Galvez topological 
charge indices 
Mean topological charge index of order 2 
E1v WHIM 1st component accessibility directional WHIM index, weighted by atomic 
van der Waals volumes 
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The PLS regression models obtained with these descriptors have resulted in the statistical 
parameters presented in Table 2. In order to reassure the suitability of the selected descriptors for 
building QSAR models for the compounds under study, other two techniques were also employed: 
Principal Component Regression (PCR) and Multiple Linear Regression (MLR). Statistical results for 
these techniques are also displayed in Table 2. There, it is possible to observe that the optimum 
number of latent variables for PLS is 1, while the optimal number of principal components for PCR is 
2, since those are the ones presenting lowest SEV (standard error of validation) and PRESS  
(cross-validation predicted residual error sum of squares) values.  
Then, applying leave-one-out (LOO) cross-validation, the best PLS model presents correlation 
coefficients of ݍ௅ைைଶ  = 0.852 and r2 = 0.874, whereas in the best PCR models these values are  
ݍ௅ைைଶ  = 0.873 and r2 = 0.852, indicating good internal consistency for both models. Leave-N-out 
(LNO) cross-validation results show that the models continue to present significant correlation 
coefficients (ݍ௅ேைଶ  = 0.850 and 0.854 for PLS and PCR, respectively) even when 30% of the samples 
are left out for prediction, which indicates that robust models were obtained. 
Table 2. Statistical parameters for the PLS, PCR and MLR models based on the 9 selected descriptors. 
PLS models PCR models 
Factors SEV PRESS r2 ࢗࡸࡻࡻ૛  ࢗࡸࡺࡻ૛ * PCs SEV PRESS r2 ࢗࡸࡻࡻ૛  ࢗࡸࡺࡻ૛ *
1 0.389 7.105 0.874 0.852 0.850 1 0.389 7.112 0.869 0.852  
2 0.401 7.571 0.885 0.843  2 0.388 7.092 0.873 0.852 0.854 
3 0.409 7.877 0.891 0.837  3 0.396 7.364 0.873 0.847  
4 0.402 7.580 0.897 0.843  4 0.407 7.804 0.877 0.838  
5 0.402 7.599 0.899 0.843  5 0.402 7.602 0.883 0.842  
6 0.398 7.450 0.899 0.845  6 0.409 7.881 0.883 0.837  
7 0.398 7.431 0.899 0.846  7 0.418 8.231 0.884 0.829  
8 0.397 7.421 0.899 0.846  8 0.443 9.234 0.884 0.810  
9 0.397 7.416 0.899 0.846  9 0.397 7.416 0.899 0.846  
MLR model 
  r2 0.899 ࢗࡸࡻࡻ૛  0.845 ࢗࡸࡺࡻ૛ * 0.842 RMSE 0.397   
* Average value of N ranging from 2 to 14. 
2.2. External Model Validation and Y-Randomization Tests 
External validation tests were applied in order to evaluate the predictive power of the QSAR models 
constructed. A plot of experimental versus predicted pIC50 values comparing the compounds in both 
training and test sets, using the three regression techniques employed here, is shown in Figure 2. The 
good agreement between the experimental and calculated values indicates that predictive models were 
obtained, since good values of external validation correlation coefficients (ݍ௘௫௧ଶ ሻ and standard errors of 
prediction (SEP) were achieved (see Table 3). These results indicate that the QSAR models constructed 
can be used to accurately predict the biological activity of other compounds within this structural class. 
Chance correlations between the dependent variable and the selected descriptors were verified 
employing the y-randomization validation. In this test, the pIC50 values are scrambled and the r2 and q2 
values are calculated. If low values for both parameters are found, then one can be sure that a true 
correlation of the descriptors with the response variable exists in the data set [16,17]. In the 20  
Molecules 2013, 18 5036 
 
 
y-randomizations performed for our data, only low values of r2 and q2 were obtained (see Table 3). So, 
this indicates that the descriptors selected by the OPS algorithm possess a true correlation with the 
dependent variable, attesting that our statistical results are not a chance correlation result. 
Figure 2. Experimental versus predicted pIC50 values of the training and test set compounds. 
PLS PCR 
MLR 
Table 3. Statistical parameters of external validation and y-randomization tests. 
Model ࢗࢋ࢚࢞૛  SEP ࢘ࢅି࢘ࢇ࢔ࢊ࢕࢓૛ * ࢗࢅି࢘ࢇ࢔ࢊ࢕࢓૛ * 
PLS 0.900 0.317 0.097 0.155 
PCR 0.904 0.312 0.143  0.055 
MLR 0.875 0.346 0.236  0.248 
* Average value of 20 Y-randomizations. 
The models obtained were ranked according to the methodology proposed by Karoly et al. [18,19], 
where ranks are compared with random numbers. The sum of ranking differences (SRD) arranges the 
models in such a way that low values of SRD are related to better models, while similar SRD values 
indicates the similarity of the models. Furthermore, the discrete distribution for a small number of 
objects (n < 14) is calculated, whereas the normal distribution is used as a reasonable approximation if 
the number of objects is large. This theoretical distribution is visualized for random numbers and can 
be used to identify SRD values for models that are far from being random, a procedure named as 
Comparison of Ranks by Random Numbers (CRNN). 
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The results for the ranking procedure are presented in Table 4 for training and test sets, while Figure 
3 shows the SRD distributions (data matrices are provided as supplemental material S2). These results 
indicate that for both training and test sets the models obtained are better (or similarly) ranked than the 
experimental values, and that the SRD values for models are not random. 
Table 4. SRD ranking of models and experimental values, p% interval and percentiles 
output for training and test sets. 
Training set Test set 
Ranking results p% Ranking results p% 
Name SRD x < SRD > = x Name SRD x < SRD > =x 
V1 * 92 1.05 10−18 1.48 10−18 V2 6 1.19 10−5 3.08 10−5 
V2 94 1.48 10−18 1.91 10−18 V4 6 1.19 10−5 3.08 10−5 
V3 108 9.18 10−18 1.10 10−17 V1 8 3.08 10−5 7.45 10−5 
V4 140 5.75 10−16 7.00 10−16 V3 12 1.73 10−4 3.88 10−4 
XX1 618 4.80 5.06 XX1 46 4.61 5.47 
Q1 684 24.67 25.64 Q1 58 24.45 27.12 
Med 732 49.24 50.40 Med 66 48.78 52.08 
Q3 778 74.96 75.88 Q3 74 73.59 76.22 
XX19 846 94.79 95.10 XX19 84 94.77 95.59 
* (V1 = PLS model, V2 = PCR model, V3 = MLR model, and V4 = experimental values). 
Figure 3. SRD-CRRN test results for (a) training and (b) test sets. 
 
(a) (b) 
2.3. Applicability Domain 
The applicability domain was defined here in terms of leverage and Studentized residuals for all 
samples in the training set. Leverage (h) is a quantity that represents a sample’s distance to the centroid 
of the training set. For the ith sample, ݄௜ ൌ ݔ௜ሺ்ܺܺሻିଵݔ௜்  (i = 1, …, m), where ݔ௜  is the descriptor  
row-vector for compound i, m is the number of query compounds, ܺ is the n ൈ k training set matrix, k 
is the number of model descriptors and n is the number of samples in the training set. A leverage value 
greater than a certain critical value for a training set sample, defined here on the basis of 95% 
confidence level, means that the sample has a high influence in the model. 
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Concerning Y outliers, the simple examination of raw y residuals can be misleading due to the effect 
of leverage. A sample with an extreme y value pulls the model towards itself, decreasing the difference 
between its experimental and fitted y values. In contrast, a sample with a y value lying close to the y 
mean value, having little leverage, do not greatly influence the model so its y residual tends to be 
higher. In order to have a more realistic picture, the Studentized residual, ri, can be applied, since it 
takes leverage into account. ri is derived from the root mean squared y residual for the training set 
(RMSE), and is given by Equation (1): 
ݎ௜ ൌ ௜݂ܴܯܵܧሺ1 െ ݄௜ሻଵ/ଶ 
(1)
Since it is assumed that ri is normally distributed, a t test can determine whether a sample’s 
Studentized residual is large enough to classify such sample as a Y outlier. Here, a critical value for ri 
was computed at a 95% probability level, based on the n training set samples. Finally, the plots of hi 
versus ri for the best PLS, PCR and MLR models were examined in order to determine the 
applicability domain of these models. Results are shown in Figure 4, where is possible to verify that 
none of the compounds from the training set can be considered as a response outlier, since all of them 
present low combined values of hi and ri. Although compound 25, in all models, and compound 42 in 
PLS and PCR present high Y residuals, both of them have extremely low leverage values, meaning 
that this outcome does not significantly influence the model. Meanwhile, compounds with relatively 
high leverage values (1, 41, 43–47 in PLS; 35, 38, 45–47 in PCR; and 40, 42, 46 and 47 in MLR) are 
inside the applicability domains of their respective models, since they are within the thresholds of ri. 
2.4. Molecular Implications for Ligand Design 
Since reliable QSAR models were obtained, the regression vectors can be used to analyze the 
selected molecular features and to suggest structural modifications that can be able to improve the 
biological activity of molecules similar to the ones studied here. The contributions of each descriptor 
to the regression vector for the best models obtained are displayed in Figure 5. 
Figure 4. Plots of leverage versus Studentized residuals for the regression models 
constructed. Blue lines indicate the thresholds representing a probability level of 95%. 
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Figure 4. Cont. 
Figure 5. Contribution of each descriptor to the regression vector. 
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ligands to biological receptors. For efficient and specific binding, the receptor cavity must be filled 
with the interacting ligand in the most optimal geometry [21]. Additionally, in this case, EHOMO must 
also have a high value, which indicates that a highly active molecule must be the one with a high 
ionization potential, meaning that it would easily donate an electron in a charge transfer mechanism [22]. 
Geometry, Topology and Atom-Weight Assembly (GETAWAY) descriptors such as H7m try to 
match 3D-molecular geometry provided by the molecular influence matrix and molecular topology 
with chemical information by using different atomic weightings (atomic mass, polarizability, van der 
Waals volume, and electronegativity) [23]. The information provided by the H7m descriptor in our 
PLS model is weighted by atomic masses, having a positive influence on the biological activity. 
BELp1 is also a 2D descriptor from the class of BCUT descriptors, which accounts for the first 
eight lowest absolute eigenvalues for the modified Burden adjacency matrix, where p refers to atomic 
polarizability and 1 is the eigenvalue rank. The ordered sequence of the lowest eigenvalues reflects the 
relevant aspects of molecular structure, which are useful for similarity searching [24]. JGI2 belongs to 
GALVEZ descriptors, which are the Galvez topological charge indices, and have their origin in the 
first 10 eigenvalues of the polynomial of corrected adjacency matrix of the compounds. JGI2 
represents the mean topological charge index of order 2 [25]. 
On the other hand, from the negative signs of regression coefficients of HATS4e, HATS3u, Mor23v 
and E1v, it is evident that these descriptors contribute negatively to the biological activity of adenosine 
compounds. Thus, lower values of these descriptors are required in order to obtain high activity 
compounds. HATS4e and HATS3u also belong to the class of GETAWAY descriptors. The HATS 
prefix means leverage-weighted autocorrelation, 4 and 3 are the lag numbers, and while HATS4e is 
weighted by atomic Sanderson electronegativities, HATS3u is unweighted [26]. The selection of the 
3D descriptors Mor23v can be related to the importance of molecular conformation of adenosine 
analogues for the interaction with key amino acids from the binding site of GAPDH [27]. E1v belongs 
to the class of Weighted Holistic Invariant Molecular (WHIM) descriptors, which contain 3D 
information calculated from the x,y,z-coordinates. E1v is the 1st component accessibility directional 
WHIM index, weighted by atomic van der Waals volumes [28].  
On the basis of the foregoing considerations, it is possible to observe a balance between steric and 
electrostatic properties influencing the affinity of adenosines to LmGAPDH, which is in agreement 
with the findings of Guido et al. [11]. Steric molecular features are represented by volume, H7m, E1v, 
and Mor23v, while descriptors EHOMO, HATS4e, BELp1, and JGI2 account for electronic aspects. 
3. Experimental 
3.1. Data Sets 
The 61 adenosine derivatives employed in this study were selected from the literature [7,29–32]. 
IC50 values, measured under the same experimental conditions, were converted to the corresponding 
pIC50 (-logIC50), and used as dependent variable in the regression analyses. Structures and pIC50 values 
for all compounds are displayed in Table 5. From the whole data set, 47 compounds were selected to 
constitute the training set, while 14 compounds were taken to compose a test set to be utilized in an 
external validation procedure. This selection was performed carefully in order to certify that the 
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structural diversity and the pIC50 distribution of the data set were well represented in both training and 
test sets. 
Table 5. Chemical structures and pIC50 values for training and test set compounds. 
Training set compounds 
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Table 5. Cont. 
Training set compounds 
Cpd Structure pIC50 Cpd Structure pIC50 
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Table 5. Cont. 
Training set compounds 
Cpd Structure pIC50 Cpd Structure pIC50 
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Table 5. Cont. 
Training set compounds 
Cpd Structure pIC50 Cpd Structure pIC50 
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Table 5. Cont. 
Training set compounds 
Cpd Structure pIC50 Cpd Structure pIC50 
47 N
N
N N
O
OH
OH
NH O
Cl Cl
NH
H3CO  
4.60 48 N
N N
N
NH2
S
NH2  
2.80 
49 
N
N
N N
NH
O
OH
OH
OH
CH3
 
3.15 50 
N
N
NH
N N
O
OH
OH
OH
 
3.44 
51 
N
N
N N
NH
O
O
OH
OH
 
3.82 52 
N
N
N
N
O
NH2
OHOH
NH
O
N
N
H  
2.52 
53 
N
N
NH2 N
N
O
NH
OH
OH
O
H5C6  
3.70  54  N
N N
N
NH2
O
OH
OH
NH
O OH
OCH3
 
3.22 
55 
NN
N
NNH
O
O
OHNH
OCH3
OCH3
 
5.30  56 
N
N
N
N
NH
O
OH
OH
NH
O
H3CO
OCH3
 
4.22 
57 
N
N
N N
NH
O
OH
OH
NH O
OC
OCH3
 
5.40  58 N
N
N N
O
OH
OH
NH O
OCH3
OH
NH
 
4.43 
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Table 5. Cont. 
Test set compounds 
Cpd Structure pIC50 Cpd Structure pIC50 
59 
N
N
N N
NH
O
OH
OH
NH O
OCH
H3CO
H3CO
 
5.70 60 N
N
N N
NH
O
OH
OH
NH O
OH
OH  
4.74 
61 
N
N
N N
NH
O
OH
OH
NH O
OCH3
O O
CH3  
5.00    
3.2. Descriptor Calculation and Selection 
A pre-optimization of the geometries of all compounds were carried out with the semiempirical 
method PM3 [33,34]. A final optimization was performed with the density functional theory (DFT) 
using the B3LYP functional [35,36] along with the 6-311G** basis sets [37]. Several electronic 
descriptors were calculated using Gaussian 03 [37], and various structural descriptors were calculated 
with the QSAR module implemented in HyperChem 4.5 [34]. A set of 1,100 molecular descriptors, 
encoding information about molecular structure, connectivity and topology were also calculated with 
Dragon 5.4 [38]. All descriptors were autoscaled in order to give them the same weight in the analyses. 
With the aim to reduce the number of descriptors, the absolute values of correlation coefficients 
between each descriptor and pIC50 were calculated. Descriptors with coefficients lower than 0.3 were 
eliminated from the analysis, and so 72 descriptors remained. From this subset of descriptors, the ones 
presenting a non-uniform distribution related to the pIC50 were also eliminated, leaving 35 descriptors 
in the analysis. Then, the Ordered Predictor Selection (OPS) algorithm [13] was employed to perform 
a variable selection. The basic idea of this algorithm is to attribute an importance to each descriptor 
based on an informative vector. The columns of the matrix are rearranged in such a way that the most 
important descriptors are presented in the first columns. Afterwards, successive PLS regressions are 
performed with an increasing number of descriptors in order to find the best PLS model. In this 
analysis, the regression vector was used as an informative vector and the correlation coefficient of 
cross-validation, q2, as a criterion to select the best models. The suitability of the descriptors selected 
by this procedure was tested by performing Principal Component Regression (PCR) and Multiple 
Linear Regression (MLR). 
The best models were chosen on the basis of the cross-validation predicted residual error sum of 
squares (PRESS), being the optimal number of PLS or PCR components the one that minimizes 
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PRESS. Model quality was verified mainly by the correlation coefficients r2 and q2 and also by the 
prediction residuals, which are indications that the model can be used for making predictions of the 
biological properties of unknown compounds, which are structurally similar. Model robustness and 
sensitiveness were additionally evaluated by applying leave-N-out (LNO) cross-validation and  
y-randomization tests. It is important to mention that the model validation is a very crucial step in 
QSAR studies [39–42]. In the LNO cross-validation procedure, N compounds (N varying from 1 to 20) 
were left out from the training set. For a particular N, the data were randomized 30 times, and the 
average and standard deviation values for q2 were used. In the y-randomization, the dependent 
variable-vector was scrambled 20 times in order to verify the occurrence of chance correlations 
between the dependent variable and the selected descriptors [16,17]. Applicability domain was defined 
through the examination of the plots of leverage versus Studentized residuals for the best PLS, PCR 
and MLR models. 
4. Conclusions 
The continuous search for new antileishmanial compounds is undoubtedly important for the 
researches in neglected diseases. In this context, QSAR models can play an important role in the 
discovery and optimization of new drug candidates. In this work, PLS, PCR and MLR models were 
developed to provide indications on relevant molecular features for the antileishmanial activity of 
adenosine compounds. A set of nine descriptors selected by the OPS approach have demonstrated to be 
suitable for the construction of QSAR models. The models constructed can be used by researchers 
interested in synthesizing new adenosine compounds. Once a new adenosine compound is designed, its 
structure can be submitted to the calculations performed in our work, i.e., the variables selected in our 
study can be calculated for this new compound. Then, the values of these variables can be inserted into 
the regression models in order to predict the pIC50 for this compound. So, our models can be helpful to 
decide which compounds should be synthesized, saving time and resources. The good statistical 
parameters, stability and robustness of the models obtained, as assured by the validation tests applied 
over our data, indicate that these models can be used to design other adenosine derivatives with 
improved antileishmanial activity. 
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